JP2023513752A5 - - Google Patents

Info

Publication number
JP2023513752A5
JP2023513752A5 JP2022548955A JP2022548955A JP2023513752A5 JP 2023513752 A5 JP2023513752 A5 JP 2023513752A5 JP 2022548955 A JP2022548955 A JP 2022548955A JP 2022548955 A JP2022548955 A JP 2022548955A JP 2023513752 A5 JP2023513752 A5 JP 2023513752A5
Authority
JP
Japan
Prior art keywords
protein
cancer
fragment
polynucleotide according
pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548955A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513752A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2021/001904 external-priority patent/WO2021162521A1/ko
Publication of JP2023513752A publication Critical patent/JP2023513752A/ja
Publication of JP2023513752A5 publication Critical patent/JP2023513752A5/ja
Pending legal-status Critical Current

Links

JP2022548955A 2020-02-14 2021-02-15 外部から導入された細胞シグナル伝達調節因子を過剰発現する免疫細胞及びその使用 Pending JP2023513752A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200018169 2020-02-14
KR10-2020-0018169 2020-02-14
PCT/KR2021/001904 WO2021162521A1 (ko) 2020-02-14 2021-02-15 외부에서 도입된 세포 신호 조절 인자를 과발현하는 면역 세포 및 이들의 용도

Publications (2)

Publication Number Publication Date
JP2023513752A JP2023513752A (ja) 2023-04-03
JP2023513752A5 true JP2023513752A5 (enExample) 2024-02-26

Family

ID=77291621

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548955A Pending JP2023513752A (ja) 2020-02-14 2021-02-15 外部から導入された細胞シグナル伝達調節因子を過剰発現する免疫細胞及びその使用

Country Status (8)

Country Link
US (1) US20230212254A1 (enExample)
EP (1) EP4105232A4 (enExample)
JP (1) JP2023513752A (enExample)
KR (1) KR20210103975A (enExample)
CN (1) CN115427451B (enExample)
AU (1) AU2021219233A1 (enExample)
TW (1) TW202146440A (enExample)
WO (1) WO2021162521A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4472742A1 (en) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
CN114774364B (zh) * 2022-04-26 2024-04-26 深圳市体内生物医药科技有限公司 一种嵌合抗原受体t细胞及其制备方法和应用
WO2024121426A1 (en) * 2022-12-09 2024-06-13 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Method for optimizing t cells for immuno-therapy
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向psma及ca9之系統
CN116376844B (zh) * 2023-05-31 2023-08-11 四川大学华西医院 包含shp2 sh2结构域的靶向her2阳性肿瘤的car-t及制备方法和应用
CN116355859B (zh) * 2023-05-31 2023-08-11 四川大学华西医院 包含shp2 n-sh2结构域的靶向her2阳性肿瘤的car-t及制备方法和应用
CN116814664B (zh) * 2023-08-25 2023-12-12 中国医学科学院肿瘤医院 一种扩展肿瘤识别表位的cea嵌合抗原受体t细胞的制备与应用
WO2025111277A2 (en) * 2023-11-20 2025-05-30 Carisma Therapeutics Inc. Compositions and methods relating to redirected soluble modulators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2447695C (en) 2001-06-01 2015-02-24 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
IL305629A (en) * 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
RS63601B1 (sr) * 2014-10-09 2022-10-31 Univ Yamaguchi Vektor ekspresije car i t ćelije koje eksprimiraju car
CA3034691A1 (en) * 2016-08-30 2018-03-08 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use for treating viral and other infections
US11654158B2 (en) * 2016-11-17 2023-05-23 2Seventy Bio, Inc. TGFBeta signal convertor
GB201620070D0 (en) * 2016-11-28 2017-01-11 Autolus Ltd Signal transduction modifying protein
WO2018138003A1 (en) * 2017-01-25 2018-08-02 Tessa Therapeutics Pte. Ltd. TGF-ß DECOY RECEPTOR
AU2018222741A1 (en) * 2017-02-17 2019-09-26 Unum Therapeutics Inc. Co-use of anti-BCMA antibody and antibody-coupled T celll receptor (ACTR) in cancer therapy and B cell disorders
AU2018227583B2 (en) * 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy
RU2019133286A (ru) * 2017-03-22 2021-04-22 Новартис Аг Биомаркеры и средства терапии на основе т-клеток с car с повышенной эффективностью
CN118853581A (zh) * 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法
CN108218999B (zh) * 2018-01-02 2021-06-11 广东省人民医院(广东省医学科学院) 分泌il-7的嵌合抗原受体、病毒载体、表达细胞及制备方法与药物
CN109265565B (zh) * 2018-10-10 2021-06-01 苏州大学 一种携带分子开关的抗CD79b嵌合抗原受体及其修饰的免疫细胞和应用
WO2020123947A1 (en) * 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes

Similar Documents

Publication Publication Date Title
JP2025028239A5 (enExample)
JP2021094037A5 (enExample)
JP2020517295A5 (enExample)
JP2018525033A5 (enExample)
RU2018135819A (ru) Иммунные эффекторные клетки с отредактированным геномом
JP2021087455A5 (enExample)
JP2021519580A5 (enExample)
FI3896091T3 (fi) BCMA:han kohdentuvia kimeerisiä antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
JP2023123502A5 (enExample)
CN111234033B (zh) 多链嵌合抗原受体及其用途
JP2024502632A5 (enExample)
JP2021519301A5 (enExample)
JP2021514631A5 (enExample)
JP2019535275A5 (enExample)
US20230248768A1 (en) Engineered immune cell for allotransplantation
JP2019527557A5 (enExample)
JP2022513460A5 (enExample)
JP2024534471A5 (enExample)
FI3334765T3 (fi) Yksidomeenivasta-aineisiin perustuvia kimeerisiä antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
WO2017176525A1 (en) Car having replicated binding motifs in a co-stimulatory domain
JP2021519072A5 (enExample)
JP2024534417A5 (enExample)
CN114015656A (zh) 用于同种异体移植的工程化免疫细胞
EP4194472A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
JP2023522038A5 (enExample)